Therapeutic Options for Binge Eating Disorder.

Therapeutic options for binge eating disorder.

Eat Weight Disord. 2013 Mar; 18(1): 3-9
Ramacciotti CE, Coli E, Marazziti D, Segura-García C, Brambilla F, Piccinni A, Dell’osso L

This article addresses the state of the art concerning the treatment of binge eating disorder (BED). Pharmacological and psychotherapeutic strategies, together with issues concerning the involvement in bariatric surgery are considered.A Medline enquiry of published articles was performed using the following keywords: BED, pharmacological treatment, duloxetine, venlafaxine, SSRI, psychotherapy, bariatric surgery; reviews and single-case studies were also analyzed.Psychological interventions that have shown efficacy in the treatment of Bulimia Nervosa have also been tested in BED with positive results, in particular modified cognitive behavioral therapy, interpersonal therapy and dialectical behavior therapy. In addition pharmacotherapy with SSRIs is successful in transiently reducing binge-eating and body weight; the SNRI duloxetine is effective for reducing binge eating, and global severity of illness with a controversial effect on body weight; both topiramate and sibutramine seem promising, but their use is restricted due to labeling and side effect limitations, respectively. Finally, adequate psychological/pharmacological support can help BED patients obtain positive outcomes from bariatric surgery.Studies on BED treatment are burdened by several limitations as selection biases (e.g. mostly women and overweight), small samples, high drop-out rates and placebo response. HubMed – eating

2013: a year of change for Eating and Weight Disorders – Studies on Anorexia, Bulimia, and Obesity.

Eat Weight Disord. 2013 Mar; 18(1): 1-2
Cuzzolaro M

HubMed – eating

mTOR and regulation of energy homeostasis in humans.

J Mol Med (Berl). 2013 Jun 12;
Mannaa M, Krämer S, Boschmann M, Gollasch M

Patients treated with the mammalian or mechanistic target of rapamycin (mTOR) inhibitor everolimus in order to slow progression of autosomal-dominant polycystic kidney disease (ADPKD) showed a significant reduction of body weight. Although the detailed mechanism of how mTOR inhibition interferes with body weight regulation is rather unclear, present data suggest that this effect is mediated by both central and peripheral mechanisms. These findings in ADPKD patients are in contrast to well-documented effects of hypothalamic mTOR on regulation of energy homeostasis and eating behavior in rodents. In a number of rodent models, the mTOR inhibitor rapamycin induces increased food intake, which is accompanied by increased body weight. However, animal data are inconsistent. This review highlights some of the regulatory signals and key mechanisms that are important for balancing energy intake and energy expenditure with a special focus on adipose tissue-derived adipokines and their interaction with mTOR regarding local regulation of tissue perfusion and metabolism and overall systemic energy homeostasis. Specifically, clinical aspects of an impaired mTOR signaling pathway regarding the development of obesity and type-2 diabetes mellitus will be discussed. HubMed – eating

THIN – Eating disorders – Part 6 – THIN, directed by Lauren Greenfield and distributed by HBO, is an exploration of The Renfrew Center in Coconut Creek, Florida; a 40-bed residential facility …